Treatment of Facial and Neck Herpes Simplex Virus Infection
For orolabial herpes (herpes labialis) on the face and neck, treat with oral valacyclovir, famciclovir, or acyclovir for 5-10 days, with severe mucocutaneous lesions requiring initial IV acyclovir followed by oral therapy until complete healing. 1
Treatment Approach by Severity
Mild to Moderate Orolabial Lesions
Oral antiviral therapy is the standard of care:
- Valacyclovir 1000 mg twice daily for 1 day (single-day therapy) 2
- Valacyclovir 500 mg twice daily for 3 days 2
- Acyclovir 400 mg three times daily for 5 days 3
- Famciclovir 500 mg twice daily for 5 days 1
The evidence shows that approximately 42-47% of facial HSV episodes abort when therapy is initiated during prodrome or within 6 hours of first symptoms 2. Early initiation is critical for maximum benefit—treatment started during prodrome/macule stages or within 6 hours significantly increases the likelihood of lesion abortion 2.
Severe Mucocutaneous Disease
For extensive or severe facial/neck HSV lesions:
- Initial treatment: Acyclovir 5-10 mg/kg IV every 8 hours 1
- Switch to oral therapy once lesions begin to regress 1
- Continue treatment until lesions completely heal 1
This approach is particularly important for immunocompromised patients who may have prolonged episodes with extensive disease 1.
Specific Dosing Regimens
First-Line Options (in order of convenience)
Valacyclovir 1000 mg twice daily for 1 day - Most convenient, proven effective with 42% lesion abortion rate 2
Valacyclovir 500 mg twice daily for 3 days - Slightly longer course with 47% abortion rate 2
Acyclovir 400 mg three times daily for 3-5 days - Well-established efficacy 3
Alternative Regimens
Special Populations
HIV-Infected or Immunocompromised Patients
- Do NOT use short-course therapy (1-3 days) 1
- Treat for 5-14 days with standard oral antivirals 1
- Consider IV acyclovir for severe disease 1
- Monitor for acyclovir resistance if lesions fail to resolve within 7-10 days 1
For acyclovir-resistant HSV (suspected when lesions don't improve after 7-10 days):
- Foscarnet 40 mg/kg IV three times daily is the treatment of choice 1
- Topical alternatives (trifluridine, cidofovir, imiquimod) may be used for external lesions but require prolonged application of 21-28 days 1
Pregnant Women
- Acyclovir is the first choice - most safety data in pregnancy 1
- Standard episodic therapy dosing can be offered 1
Topical Therapy
Topical treatments have limited efficacy compared to oral therapy:
- 5% acyclovir cream may reduce lesion duration if applied very early 3
- Topical therapy is substantially less effective than oral drugs 1
- Topical use is generally discouraged as primary therapy 1
Suppressive Therapy for Frequent Recurrences
For patients with ≥6 recurrences per year, consider daily suppressive therapy:
- Acyclovir 400 mg twice daily 1
- Valacyclovir 500-1000 mg twice daily 3
- Famciclovir 250 mg twice daily 1
Suppressive therapy reduces recurrence frequency by ≥75% 1. After 1 year of continuous therapy, reassess the need for continuation 1.
Critical Pitfalls to Avoid
Do not delay treatment - Efficacy drops dramatically if not started within 6 hours of symptom onset or during prodrome 2
Do not use topical acyclovir as primary therapy - It is substantially less effective than oral formulations 1
Do not use short-course therapy in immunocompromised patients - They require full 5-14 day courses 1
Do not ignore treatment failure - If lesions don't improve within 7-10 days, suspect acyclovir resistance and obtain viral culture with susceptibility testing 1
Monitor renal function with IV acyclovir - Dose adjustment may be necessary 1
Monitoring and Adverse Events
- Oral antivirals (acyclovir, valacyclovir, famciclovir) are generally well-tolerated with occasional nausea or headache 1
- No routine laboratory monitoring needed for oral therapy unless significant renal impairment exists 1
- For IV acyclovir: Monitor renal function at initiation and once or twice weekly during treatment 1